These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 33507480)

  • 1. Characterization of chemotherapy-induced peripheral neuropathy using patient-reported outcomes and quantitative sensory testing.
    Zhi WI; Baser RE; Kwon A; Chen C; Li SQ; Piulson L; Seluzicki C; Panageas KS; Harte SE; Mao JJ; Bao T
    Breast Cancer Res Treat; 2021 Apr; 186(3):761-768. PubMed ID: 33507480
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemotherapy-induced peripheral neuropathy (CIPN) in breast cancer survivors: a comparison of patient-reported outcomes and quantitative sensory testing.
    Zhi WI; Chen P; Kwon A; Chen C; Harte SE; Piulson L; Li S; Patil S; Mao JJ; Bao T
    Breast Cancer Res Treat; 2019 Dec; 178(3):587-595. PubMed ID: 31456070
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanistic and thermal characterization of acupuncture for chemotherapy-induced peripheral neuropathy as measured by quantitative sensory testing.
    Zhi WI; Baser RE; Talukder D; Mei YZ; Harte SE; Bao T
    Breast Cancer Res Treat; 2023 Feb; 197(3):535-545. PubMed ID: 36527520
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exploring the reliability and validity of clinically-relevant outcome measures for chemotherapy-induced peripheral neuropathy.
    Knoerl R; Sohn MB; Spath K; Burnette B; Francar L; Mustian KM; Shah D; Gauthier L; Gewandter JS
    Support Care Cancer; 2024 Sep; 32(10):675. PubMed ID: 39297964
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Age-related differences in patient-reported and objective measures of chemotherapy-induced peripheral neuropathy among cancer survivors.
    Wong ML; Cooper BA; Paul SM; Abrams G; Topp K; Kober KM; Chesney MA; Mazor M; Schumacher MA; Conley YP; Levine JD; Miaskowski C
    Support Care Cancer; 2019 Oct; 27(10):3905-3912. PubMed ID: 30770977
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term chemotherapy-induced peripheral neuropathy among breast cancer survivors: prevalence, risk factors, and fall risk.
    Bao T; Basal C; Seluzicki C; Li SQ; Seidman AD; Mao JJ
    Breast Cancer Res Treat; 2016 Sep; 159(2):327-33. PubMed ID: 27510185
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of Patients With and Without Painful Peripheral Neuropathy After Receiving Neurotoxic Chemotherapy: Traditional Quantitative Sensory Testing vs C-Fiber and Aδ-Fiber Selective Diode Laser Stimulation.
    Nemenov MI; Alaverdyan H; Burk C; Roles K; Frey K; Yan Y; Kazinets G; Haroutounian S
    J Pain; 2022 May; 23(5):796-809. PubMed ID: 34896646
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Health-Related Quality of Life in Cancer Survivors with Chemotherapy-Induced Peripheral Neuropathy: A Randomized Clinical Trial.
    Bao T; Baser R; Chen C; Weitzman M; Zhang YL; Seluzicki C; Li QS; Piulson L; Zhi WI
    Oncologist; 2021 Nov; 26(11):e2070-e2078. PubMed ID: 34390283
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acupuncture for Chemotherapy-Induced Peripheral Neuropathy in Breast Cancer Survivors: A Randomized Controlled Pilot Trial.
    Lu W; Giobbie-Hurder A; Freedman RA; Shin IH; Lin NU; Partridge AH; Rosenthal DS; Ligibel JA
    Oncologist; 2020 Apr; 25(4):310-318. PubMed ID: 32297442
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient-Reported Outcome Measures in Chemotherapy-Induced Peripheral Neurotoxicity: Defining Minimal and Clinically Important Changes.
    Li T; Timmins HC; Trinh T; Mizrahi D; Harrison M; Horvath LG; Grimison P; Friedlander M; Kiernan MC; King MT; Rutherford C; Goldstein D; Park SB
    J Natl Compr Canc Netw; 2023 Feb; 21(2):125-132.e3. PubMed ID: 36791763
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Validity of Patient-Reported Outcome Measures in Evaluating Nerve Damage Following Chemotherapy.
    Li T; Timmins HC; Mahfouz FM; Trinh T; Mizrahi D; Horvath LG; Harrison M; Grimison P; Friedlander M; Marx G; Boyle F; Wyld D; Henderson R; King T; Baron-Hay S; Kiernan MC; Rutherford C; Goldstein D; Park SB
    JAMA Netw Open; 2024 Aug; 7(8):e2424139. PubMed ID: 39120903
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimizing Clinical Screening for Chemotherapy-Induced Peripheral Neuropathy.
    McCrary JM; Goldstein D; Trinh T; Timmins HC; Li T; Friedlander M; Bosco A; Harrison M; Maier N; O'Neill S; Park SB
    J Pain Symptom Manage; 2019 Dec; 58(6):1023-1032. PubMed ID: 31374367
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Redefining chemotherapy-induced peripheral neuropathy through symptom cluster analysis and patient-reported outcome data over time.
    Wang M; Cheng HL; Lopez V; Sundar R; Yorke J; Molassiotis A
    BMC Cancer; 2019 Nov; 19(1):1151. PubMed ID: 31775665
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of exercise on chemotherapy-induced peripheral neuropathy in survivors with post-treatment primary breast cancer.
    Saint K; Nemirovsky D; Lessing A; Chen Y; Yang M; Underwood WP; Galantino ML; Jones LW; Bao T
    Breast Cancer Res Treat; 2024 Aug; 206(3):667-675. PubMed ID: 38713289
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Subclinical Peripheral Neuropathy in Patients with Head and Neck Cancer: A Quantitative Sensory Testing (QST) Study.
    Roldan CJ; Johnson C; Lee SO; Peng A; Dougherty PM; Huh B
    Pain Physician; 2018 Jul; 21(4):E419-E427. PubMed ID: 30045608
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hemoglobin, Body Mass Index, and Age as Risk Factors for Paclitaxel- and Oxaliplatin-Induced Peripheral Neuropathy.
    Mizrahi D; Park SB; Li T; Timmins HC; Trinh T; Au K; Battaglini E; Wyld D; Henderson RD; Grimison P; Ke H; Geelan-Small P; Marker J; Wall B; Goldstein D
    JAMA Netw Open; 2021 Feb; 4(2):e2036695. PubMed ID: 33587134
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of Chemotherapy-Induced Peripheral Neuropathy on Quality of Life in Patients with Advanced Lung Cancer Receiving Platinum-Based Chemotherapy.
    Hung HW; Liu CY; Chen HF; Chang CC; Chen SC
    Int J Environ Res Public Health; 2021 May; 18(11):. PubMed ID: 34073174
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostic tools should be used for the diagnosis of chemotherapy induced peripheral neuropathy in breast cancer patients receiving taxanes.
    van Haren F; van den Heuvel S; Ligtenberg M; Vissers K; Steegers M
    Cancer Rep (Hoboken); 2022 Oct; 5(10):e1577. PubMed ID: 34687287
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of mirogabalin for chemotherapy-induced peripheral neuropathy: a prospective single-arm trial (MiroCIP study).
    Misawa S; Denda T; Kodama S; Suzuki T; Naito Y; Kogawa T; Takada M; Suichi T; Shiosakai K; Kuwabara S;
    BMC Cancer; 2023 Nov; 23(1):1098. PubMed ID: 37951905
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vibration Perception Threshold and Heart Rate Variability as methods to assess chemotherapy-induced neuropathy in women with breast cancer - a pilot study.
    Marstrand SD; Buch-Larsen K; Andersson M; Jensen LT; Schwarz P
    Cancer Treat Res Commun; 2021; 28():100426. PubMed ID: 34186438
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.